Clinical trial · no report yet · Phase 3
CURB2
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
- NCT06686771 ↗
- Recruiting
- Canadian Cancer Trials Group
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 24 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SBRT; First or second-line standard of care therapy
- Arms
- SBRT/Radiotherapy followed by standard of care therapy · Experimental
- Systemic therapy at the investigator's discretion, no SBRT · Active comparator
- Enrollment
- 320 (estimated)
- Primary outcomes
- Progression-free survival
- Overall survival
- Sponsor
- Canadian Cancer Trials Group with Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network
- Start
- Dec 16, 2025
- Primary completion
- Feb 28, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06686771 · updated Jul 14, 2026